Drug Search Results
More Filters [+]

Crizanlizumab

Alternative Names: crizanlizumab, seg-101, seg101, seg 101, crizanlizumab-tmca, ADAKVEO, SelG1
Latest Update: 2024-09-23
Latest Update Note: Clinical Trial Update

Product Description

For Retinal Vasculopathy Cerebral Leukoencephalopathy; crizanlizumab is a humanized monoclonal anti-P-selectin antibody that prevents leukocyte adhesion to the vascular endothelium, thereby limiting risk of microvascular occlusion (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04611880)

Mechanisms of Action: P-selectin Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Austria | Belgium | Brazil | Colombia | Croatia | Cyprus | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Israel | Italy | Jordan | Latvia | Lebanon | Lithuania | Luxembourg | Netherlands | Norway | Poland | Portugal | Saudi Arabia | Slovakia | Spain | Sweden | United Arab Emirates | United Kingdom | United States

Approved Indications: Anemia, Sickle Cell

Known Adverse Events: Back Pain | Pain Unspecified | Arthralgia

Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Crizanlizumab

Countries in Clinic: Belgium, Brazil, Canada, Colombia, Finland, France, Germany, Ghana, Greece, India, Ireland, Italy, Jordan, Lebanon, Netherlands, Oman, Panama, South Africa, Spain, Switzerland, Turkey, United Kingdom, United States

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Anemia, Sickle Cell

Phase 2: Kidney Failure, Chronic|Priapism

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

SPARKLE

P3

Not yet recruiting

Anemia, Sickle Cell

2029-03-23

56%

SEG101

P2

Not yet recruiting

Anemia, Sickle Cell

2028-07-01

STAND

P3

Unknown status

Anemia, Sickle Cell

2027-11-08

CSEG101A2301

P3

Unknown Status

Anemia, Sickle Cell

2026-12-14

Recent News Events